Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 14/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 12/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 11/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 10/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 10/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.40 |
| ▸ | CYP2E1 | P05181 | 10/20 | 0.40 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.38 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 4/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10130683 | 0.85 | RORC (0.49) | RORCCYP2A6CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL13699254 | 0.85 | CYP2A6 (0.59) | CYP2A6CYP2C19CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL10162016 | 0.80 | CYP2A6 (0.46) | RORCCYP2A6CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL13699263 | 0.76 | CYP2D6 (0.39) | CYP2A6CYP2C19CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL13514034 | 0.73 | SLC5A2 (0.37) | CYP2A6CYP2C19CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL27398576 | 0.73 | CYP2A6 (0.69) | RORCCYP2A6CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL13699203 | 0.71 | KDM4E (0.53) | CYP1A2 | |
| SCHEMBL13003925 | 0.70 | ATM (0.41) | CYP2A6 | |
| SCHEMBL10130586 | 0.70 | CYP2A6 (0.64) | CYP2A6CYP2C19CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL21608633 | 0.70 | LTA4H (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589067-B2 | 6, 11-bridged tricyclic macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | ENANTA PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | CYP2B6, CYP2D6, ABCB11 | RORC 901/4885CYP2A6 4/4885CYP2C19 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.